疑似冠心病患者解剖与功能影像检查后降脂药物治疗与结局的关系
连续1973例疑似阻塞性冠心病患者接受冠状动脉CT血管成像,未排除阻塞者进一步行正电子发射断层显像缺血试验,随访中位6.7年。降脂药物使用率随影像所定义的冠心病表型递增:无冠心病24%、非阻塞性51%、阻塞性无心肌缺血72%、心肌缺血91%;降脂药物使用与心肌缺血患者(年事件率6.1% vs 2.8%,P=0.032)及阻塞性无心肌缺血患者(2.9% vs 1.4%,P=0.004)较低年不良事件率相关,而在非阻塞性(1.5% vs 1.4%,P=0.89)或无冠心病(0.3% vs 0.3%,P=0.68)患者中无显著关联。
要点
- 影像定义的表型指导降脂药物使用:心肌缺血者91%用药,无冠心病者24%用药。
- 心肌缺血患者用药年事件率6.1% vs 未用药2.8%,P=0.032。
- 阻塞性无心肌缺血者用药年事件率2.9% vs 未用药1.4%,P=0.004。
核心结论
- 解剖与功能影像定义的冠心病表型指导降脂药物使用;心肌缺血和 anatomical obstructive coronary lesions 的存在与降脂药物的长期结局获益相关。
研究设计与样本
- 连续1973例疑似阻塞性冠心病患者(41%男性,中位年龄63岁)接受冠状动脉CT血管成像,未排除阻塞性冠心病者行正电子发射断层显像缺血试验;收集至2年的降脂药物购买数据,中位6.7年评估死亡、心肌梗死和不稳定型心绞痛复合终点。
诊断标准与关键数值
- 影像后降脂药物使用率:无冠心病24%,非阻塞性冠心病51%,CT血管成像阻塞性冠心病无心肌缺血72%,心肌缺血91%。
- 随访期间降脂药物使用下降,心肌缺血患者中77%使用降脂药物达2年。
- 降脂药物使用与较低年不良事件率相关:心肌缺血患者6.1% vs 2.8%(P=0.032),阻塞性冠心病无心肌缺血患者2.9% vs 1.4%(P=0.004)。
- 非阻塞性冠心病患者年不良事件率1.5% vs 1.4%(P=0.89),无冠心病患者0.3% vs 0.3%(P=0.68),均无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Anatomical and functional imaging identify different phenotypes of coronary artery disease (CAD) that may have implications for lipid-lowering medication (LLM).
OBJECTIVES: The aim of this study was to assess the associations between LLM and long-term outcomes after combined anatomical and functional imaging in patients with suspected obstructive CAD.
METHODS: Consecutive patients (n = 1,973; 41% men; median age: 63 years) underwent coronary computed tomography angiography (CTA) because of suspected CAD. Patients in whom obstructive CAD was not ruled out by CTA underwent ischemia testing by positron emission tomography. Data on LLM purchases were collected until 2 years, and the combined endpoints of death, myocardial infarction, and unstable angina pectoris were assessed at a median of 6.7 years.
RESULTS: After imaging, LLM was used by 24% of patients with no CAD, 51% of patients with nonobstructive CAD, 72% of patients with obstructive CAD on CTA without myocardial ischemia, and 91% of patients with myocardial ischemia. The use of LLM decreased during follow-up, with 77% of patients with myocardial ischemia using LLM for 2 years. The use of LLM was associated with a lower annual rate of adverse events in patients with myocardial ischemia (6.1% vs 2.8%; P = 0.032) or obstructive CAD without myocardial ischemia (2.9% vs 1.4%; P = 0.004) but not in patients with nonobstructive CAD (1.5% vs 1.4%; P = 0.89) or no CAD (0.3% vs 0.3%; P = 0.68).
CONCLUSIONS: The CAD phenotype defined by anatomical and functional imaging guides the use of LLM. The presence of myocardial ischemia and anatomical obstructive coronary lesions were associated with a long-term outcome benefit from LLM.
引用
- Maaniitty T, Mäenpää M, Harjulahti E, et al. Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease. JACC Cardiovasc Imaging. 2024. PMID: 39207334. doi:10.1016/j.jcmg.2024.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。